Drug Profile
pUDK HGF
Alternative Names: pUDK-HGFLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Humanwell Healthcare
- Developer Humanwell Healthcare; XuanWu Hospital Capital Medical University
- Class Analgesics; Anti-ischaemics; Gene therapies; Vascular disorder therapies
- Mechanism of Action Gene transference; Hepatocyte growth factor expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic limb-threatening ischemia; Neuropathic pain; Postoperative pain
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Postoperative-pain in China (IM, Injection)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Postoperative-pain in China (Intrathecal, Injection)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Neuropathic-pain in China (Intrathecal, Injection)